Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Mol Cancer Ther. 2013 Feb 20;12(5):759–767. doi: 10.1158/1535-7163.MCT-12-0903

Figure 1. FoxM1 is critical for the survival and tumorigenicity of p53 null thymic lymphoma and sarcoma.

Figure 1

A-C, CreERT2, Foxm1 fl/fl and p53 −/− thymic lymphoma (represented by “L1” and “L2”) and Foxm1 fl/fl and p53 −/− thymic lymphoma (represented by “C”) were treated with ethanol as vehicle or 800nM of 4OH-tamoxifen (Tam). D, CreERT2, Foxm1 fl/fl and p53 −/− sarcoma (represented by “S”) was treated with ethanol as vehicle or 800nM of 4OH-tamoxifen (Tam). Sarcoma line stably transduced with FoxM1 expression was constructed (S: FoxM1) and treated with 800nM of 4OH-tamoxifen. Cell viability was measured by proportional luminescence signal generated by celltiter-glo assay.